A recent study has revealed a significant increase in the use of GLP-1 obesity drugs among American children under the age of 12. The rate of prescriptions for these medications has risen 300 times compared to seven years ago. Over 20,000 children aged 8 to 11 have been prescribed GLP-1 drugs since 2019, primarily those suffering from severe obesity and associated health issues. These drugs, which are typically used to help manage weight by reducing appetite and slowing digestion, are not officially approved by the U.S. Food and Drug Administration (FDA) for children under 12. However, doctors are legally allowed to prescribe them "off-label," meaning they are used for conditions or age groups not specifically approved by the FDA, based on clinical guidelines and medical judgment. The decision to prescribe GLP-1 drugs to young children is not taken lightly. Medical experts argue that the potential benefits of these medications—such as preventing long-term health complications like type 2 diabetes and heart disease—may outweigh the risks, especially for children with severe obesity. These conditions can lead to a host of health problems and significantly reduce quality of life, making early intervention a priority for many healthcare providers. Despite the growing use of GLP-1 drugs in children, the medical community is still gathering data on their long-term effects. Clinical trials are currently underway to evaluate the safety and effectiveness of these medications in younger children, including those as young as six years old. Researchers are closely monitoring for any side effects and assessing how well the drugs work in this age group. The rise in prescriptions highlights both the growing concern over childhood obesity and the evolving approach to treating it. While GLP-1 drugs are showing promise, their use in children remains a topic of ongoing research and debate within the medical field. Doctors and scientists continue to work toward ensuring that these treatments are both effective and safe for young patients.